(VIANEWS) – CRISPR Therapeutics AG (CRSP), Nucor Corporation (NUE), Axcelis Technologies (ACLS) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. CRISPR Therapeutics AG (CRSP)

500% sales growth and 25.41% return on equity

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases.

CRISPR Therapeutics AG’s sales growth this year is expected to be 114341% and a negative 94.3% for next year.

Year-on-year quarterly revenue growth grew by 2046950%, now sitting on 901.76M for the twelve trailing months.

Volume

Today’s last reported volume for CRISPR Therapeutics AG is 1851450 which is 49.29% above its average volume of 1240100.

CRISPR Therapeutics AG’s sales growth for the next quarter is 500%. The company’s growth estimates for the present quarter and the next is a negative 33.3% and negative -21.3%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.41%.

Volatility

CRISPR Therapeutics AG’s last day, last week, and last month’s current volatility was 1.75%, 2.75%, and 2.79%, respectively.

CRISPR Therapeutics AG’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.27% (day), 4.58% (last week), and 4.48% (last month), respectively.

CRISPR Therapeutics AG’s Stock Yearly Top and Bottom Value

CRISPR Therapeutics AG’s stock is valued at $97.00 at 16:22 EST, way below its 52-week high of $220.20 and way above its 52-week low of $84.38.

CRISPR Therapeutics AG’s Moving Average

CRISPR Therapeutics AG’s value is way under its 50-day moving average of $113.32 and way below its 200-day moving average of $121.85.

Previous days news about CRISPR Therapeutics AG(CRSP)

  • According to Benzinga on Thursday, 14 October, "To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. "

2. Nucor Corporation (NUE)

71.8% sales growth and 27.49% return on equity

Nucor Corporation manufactures and sells steel and steel products.

Nucor Corporation’s sales growth this year is anticipated to be 71.6% and a negative 11.5% for next year.

Year-on-year quarterly revenue growth grew by 103.1%, now sitting on 25.99B for the twelve trailing months.

Volume

Today’s last reported volume for Nucor Corporation is 2434140 which is 27.81% below its average volume of 3372060.

Nucor Corporation’s sales growth for the next quarter is 71.8%. The company’s growth estimates for the current quarter and the next is 884.6% and 345.7%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.49%.

Volatility

Nucor Corporation’s last day, last week, and last month’s current volatility was 0.89%, 0.86%, and 2.64%, respectively.

Nucor Corporation’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.13% (day), 2.79% (last week), and 3.74% (last month), respectively.

Nucor Corporation’s Stock Yearly Top and Bottom Value

Nucor Corporation’s stock is valued at $101.78 at 16:22 EST, way under its 52-week high of $128.81 and way above its 52-week low of $46.00.

Nucor Corporation’s Moving Average

Nucor Corporation’s worth is under its 50-day moving average of $106.28 and higher than its 200-day moving average of $99.43.

3. Axcelis Technologies (ACLS)

43.6% sales growth and 12.96% return on equity

Axcelis Technologies, Inc. designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips worldwide.

Axcelis Technologies’s sales growth this year is expected to be 31.8% and 10.4% for next year.

Year-on-year quarterly revenue growth grew by 19.8%, now sitting on 512.65M for the twelve trailing months.

Volume

Today’s last reported volume for Axcelis Technologies is 22757 which is 89.98% below its average volume of 227183.

Axcelis Technologies’s sales growth for the next quarter is 43.6%. The company’s growth estimates for the current quarter and the next is 131.2% and 134.4%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.96%.

Volatility

Axcelis Technologies’s last day, last week, and last month’s current volatility was 2.67%, 1.81%, and 2.13%, respectively.

Axcelis Technologies’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.48% (day), 3.58% (last week), and 3.34% (last month), respectively.

Axcelis Technologies’s Stock Yearly Top and Bottom Value

Axcelis Technologies’s stock is valued at $48.42 at 16:22 EST, under its 52-week high of $52.80 and way above its 52-week low of $21.69.

Axcelis Technologies’s Moving Average

Axcelis Technologies’s value is under its 50-day moving average of $48.52 and way higher than its 200-day moving average of $42.73.

4. Astrazeneca (AZN)

43% sales growth and 25.67% return on equity

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide.

Astrazeneca’s sales growth this year is anticipated to be 35.1% and 15.7% for next year.

Year-on-year quarterly revenue growth grew by 31%, now sitting on 29.53B for the twelve trailing months.

Volume

Today’s last reported volume for Astrazeneca is 3501960 which is 63.85% below its average volume of 9688270.

Astrazeneca’s sales growth for the next quarter is 43%. The company’s growth estimates for the present quarter and the next is 40.4% and 45.3%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.67%.

Volatility

Astrazeneca’s last day, last week, and last month’s current volatility was 1.31%, 0.70%, and 1.41%, respectively.

Astrazeneca’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.59% (day), 1.14% (last week), and 1.60% (last month), respectively.

Astrazeneca’s Stock Yearly Top and Bottom Value

Astrazeneca’s stock is valued at $60.22 at 16:22 EST, under its 52-week high of $61.34 and way above its 52-week low of $46.48.

Astrazeneca’s Moving Average

Astrazeneca’s value is above its 50-day moving average of $58.70 and higher than its 200-day moving average of $56.67.

5. Rexford Industrial Realty (REXR)

30% sales growth and 3.07% return on equity

Rexford Industrial, a real estate investment trust focused on owning and operating industrial properties throughout Southern California infill markets, owns 232 properties with approximately 27.9 million rentable square feet and manages an additional 20 properties with approximately 1.0 million rentable square feet.

Rexford Industrial Realty’s sales growth this year is anticipated to be 31% and 17.6% for next year.

Year-on-year quarterly revenue growth grew by 30.5%, now sitting on 376.63M for the twelve trailing months.

Volume

Today’s last reported volume for Rexford Industrial Realty is 1120880 which is 32.75% above its average volume of 844298.

Rexford Industrial Realty’s sales growth for the next quarter is 30%. The company’s growth estimates for the present quarter and the next is a negative 42.9% and 20%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.07%.

Volatility

Rexford Industrial Realty’s last day, last week, and last month’s current volatility was 1.37%, 1.17%, and 1.50%, respectively.

Rexford Industrial Realty’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.57% (day), 1.64% (last week), and 1.73% (last month), respectively.

Rexford Industrial Realty’s Stock Yearly Top and Bottom Value

Rexford Industrial Realty’s stock is valued at $60.69 at 16:22 EST, under its 52-week high of $63.55 and way above its 52-week low of $45.90.

Rexford Industrial Realty’s Moving Average

Rexford Industrial Realty’s value is higher than its 50-day moving average of $59.75 and higher than its 200-day moving average of $57.85.

6. Zoom (ZM)

15.3% sales growth and 34.26% return on equity

Zoom Video Communications, Inc. provides a video-first communications platform in the Americas, the Asia Pacific, Europe, the Middle East, and Africa.

Zoom’s sales growth this year is expected to be 51.5% and 18% for next year.

Year-on-year quarterly revenue growth grew by 191.4%, now sitting on 3.28B for the twelve trailing months.

Volume

Today’s last reported volume for Zoom is 2751130 which is 37.77% below its average volume of 4421410.

Zoom’s sales growth is a negative 0% for the current quarter and 15.3% for the next. The company’s growth estimates for the present quarter and the next is 10.1% and negative -13.9%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 34.26%.

Volatility

Zoom’s last day, last week, and last month’s current volatility was 0.29%, 1.20%, and 2.10%, respectively.

Zoom’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.68% (day), 2.78% (last week), and 2.97% (last month), respectively.

Zoom’s Stock Yearly Top and Bottom Value

Zoom’s stock is valued at $266.32 at 16:22 EST, way under its 52-week high of $588.84 and higher than its 52-week low of $250.11.

Zoom’s Moving Average

Zoom’s worth is below its 50-day moving average of $283.70 and way under its 200-day moving average of $330.15.

Previous days news about Zoom(ZM)

  • According to VentureBeat on Wednesday, 13 October, "With another $275 million in the bank and a host of freshly acquired enterprise clients including Snowflake and Heineken on top of existing customers such as Zoom and Box, TripActions is in a strong position to capitalize as corporate travel slowly resumes."
  • According to VentureBeat on Tuesday, 12 October, "Activities necessitated by the pandemic such as remote work from home, virtual Zoom meets with friends and relatives, first-run movie streaming, online shopping, exercise, gaming, and ordering food are becoming the norm now and going forward. "
  • According to Bloomberg Quint on Wednesday, 13 October, "Cisco also missed an opportunity to have its own pandemic consumer hit when Zoom Video Communications surpassed Webex as the household name for videoconferencing. ", "The perception now is that Zoom has considerable market share advantage." Cisco pushes back on this, saying Webex is the favored choice of corporate clients, who value its stability and security, but the company doesn’t report metrics that allow for a direct comparison."

7. EMCOR Group (EME)

7.5% sales growth and 16.02% return on equity

EMCOR Group, Inc. provides electrical and mechanical construction, and facilities services in the United States.

EMCOR Group’s sales growth this year is anticipated to be 8.9% and 5.3% for next year.

Year-on-year quarterly revenue growth grew by 21%, now sitting on 9.22B for the twelve trailing months.

Volume

Today’s last reported volume for EMCOR Group is 180564 which is 21.3% below its average volume of 229454.

EMCOR Group’s sales growth for the next quarter is 7.5%. The company’s growth estimates for the present quarter and the next is 0.6% and negative -0.5%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.02%.

Volatility

EMCOR Group’s last day, last week, and last month’s current volatility was 0.53%, 0.83%, and 1.41%, respectively.

EMCOR Group’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.70% (day), 1.77% (last week), and 2.47% (last month), respectively.

EMCOR Group’s Stock Yearly Top and Bottom Value

EMCOR Group’s stock is valued at $116.17 at 16:22 EST, way under its 52-week high of $129.45 and way higher than its 52-week low of $63.69.

EMCOR Group’s Moving Average

EMCOR Group’s value is under its 50-day moving average of $118.43 and under its 200-day moving average of $120.55.

LEAVE A REPLY

Please enter your comment!
Please enter your name here